Intravenous Itraconazole vs. Amphotericin B Deoxycholate for Empirical Antifungal Therapy in Patients with Persistent Neutropenic Fever

키워드

참고문헌 (24)

1. "Empirical antifungal therapy in treating febrile neutropenic patients", 39(Suppl 1), pp.38~43 (2004)
2. "Empirical antifungal therapy: new options, new tradeoffs", 346, pp.278~280 (2002)
3. "Empirical antifungal therapy", 23, pp.105~112 (2004)
4. "Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia: National Institute for Allergy and Infectious Diseases Mycoses Study Group", 340, pp.764~771 (1999)
5. "Analysis of invasive fungal infection after hematopoietic stem cell transplantation or chemotherapy in patients with hematologic diseases", 36, pp.40~45 (2004)
6. "Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia", 72, pp.101~111 (1982)
7. "Empiric antifungal therapy in febrile granulocytopenic patients", 86, pp.668~672 (1989)
8. "Response to empiric amphotericin B during antileukemic therapy:induced granulocytopenia", 13, pp.592~599 (1991)
9. "Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever", 346, pp.225~234 (2002)
10. "Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia", 351, pp.1391~1402 (2004)
11. "Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy: a randomized, controlled trial", 135, pp.412~422 (2001)
12. "Organism-dependent fungicidal activities of azoles", 42, pp.3018~3021 (1998)
13. "In vitro activity of itraconazole against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients infected with human immunodeficiency virus", 38, pp.1530~1533 (1994)
14. "Forum report: issues in clinical trials of empirical antifungal therapy in treating febrile neutropenic patients", 36(Suppl 3), pp.117~122 (2003)
15. "Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus", 34, pp.7~14 (2002)
16. "Rare and emerging opportunistic fungal pathogens:concern for resistance beyond Candida albicans and Aspergillus fumigatus", 42, pp.4419~4431 (2004)
17. "A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer", 108, pp.282~289 (2000)
18. "Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia", 27, pp.296~302 (1998)
19. "A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia: L Amph", ABLC Collaborative Study Group, 2000, pp.31, 1155~1163
20. "Adverse events associated with itraconazole in 189 patients on chronic therapy", 26, pp.561~566 (1990)
21. "Development of interpretive breakpoints for antifungal susceptibility testing conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole Subcommittee on antifungal susceptibility testing of the National Committee for Clinical Laboratory Standards", 24, pp.235~247 (1997)
22. "Making sense of itraconazole pharmacokinetics", 56(Suppl 1), pp.17~22 (2005)
23. "The place for itraconazole in treatment", 56(Suppl 1), pp.33~38 (2005)
24. "Cyclophosphamide metabolism is affected by azole antifungals", 103, pp.1557~1559 (2004)

관련 논문AI추천